Intellia Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
NTLA News
William Blair downgraded Intellia Therapeutics (NTLA) to Market Perform from Outperform after the company announced that it has voluntarily paused enrollment an...
(RTTNews) - Intellia Therapeutics, Inc. (NTLA) fell 43.79% to $14.39, down $11.21, after providing an update on its Magnitude Phase 1/2 clinical trials evaluati...
Guggenheim analyst Debjit Chattopadhyay downgraded Intellia Therapeutics (NTLA) to Neutral from Buy. Published first on TheFly – the ultimate source for real-t...
Analyst ratings
81%
of 26 ratingsMore NTLA News
Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized Intellia dropped sharply on Monday after it announced that...
In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Intellia Therapeutics, with a price target of $25.00. Elevate Your I...
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy rating on the shares after the company paused dosing and sc...
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE a...
Intellia Therapeutics (NTLA) stock plummeted on Monday after the biotechnology company announced an update from its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical t...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...